1	Toxicology
2	Full Paper
3	Serum levels of Ochratoxin A in dogs with chronic kidney disease (CKD): a retrospective
4	study
5	
6	RUNNING HEAD: OCHRATOXIN A IN DOGS WITH CKD
7	
8	Meucci Valentina*, Luci Giacomo, Vanni Michele, Guidi Grazia, Perondi Francesca and Intorre
9	Luigi
10	Department of Veterinary Science, University of Pisa, Italy
11	
12	*Corresponding author: Valentina Meucci, Department of Veterinary Science, University of Pisa,
13	Via Livornese lato monte, 56122, San Piero a Grado, Pisa, Italy; Tel: +39 050 2210124, Fax: +39
14	050 2210182; E-mail: valentinam@vet.unipi.it

17 ABSTRACT

Ochratoxin A (OTA) is a mycotoxin produced by secondary metabolism of several fungi 18 belonging to the genera Aspergillus and Penicillium. OTA is potentially nephrotoxic, neurotoxic, 19 immunotoxic and carcinogenic in several animal species and in humans. This toxin has been 20 detected in several human food and animal feed. The aim of this study was to determine OTA in 21 blood samples of healthy and affected by chronic kidney disease (CKD) dogs. CKD group showed 22 higher incidence of OTA-positivity than healthy dogs (96% vs 56%) and a significantly higher 23 median value of OTA plasma concentration (0.008 ng/ml vs 0.144 ng/ml). No significant 24 correlation was observed between OTA levels and creatinine values in CKD dogs. This is first 25 study regarding OTA detection in plasma samples of healthy and CKD dogs; the presence of this 26 toxin is higher in nephropatic patients but is not yet clear, if it is correlated with progression of the 27 disease. 28

29 KEY WORDS: chronic kidney disease, dog, nephrotoxin, Ochratoxin A

Chronic kidney disease (CKD) is one of the most common kidney disease in dogs, and its 31 etiology is not fully clarified; it seem correlated with some "risk factors", such as immunomediated 32 diseases, systemic or urinary tract infections, nephrolithiasis, drug or substance nephrotoxicity, 33 systemic and glomerular hypertension, chronic hypoperfusion, amyloidosis and others [29]. Several 34 well-known associations exist between CKD and both environmental agents and conditions, such as 35 heavy metals, mycotoxins, industrial chemicals and infections. An environmental factor that may be 36 associated with CKD in animals and human is Ochratoxin A (OTA). Ochratoxins are a group of 37 secondary metabolites of the Aspergillus and Penicillium genera and contaminate cereals, coffee, 38 39 dried fruit and other products. This group consists of OTA (Fig. 1), its methyl ester, its ethyl ester (Ochratoxin C), 4-hydroxyochratoxin A, Ochratoxin B with its methyl and ethyl esters and 40 Ochratoxin a. OTA is the most prevalent and toxic of the ochratoxins. Initial symptoms of 41 ochratoxicosis observed in all species include anorexia, polydipsia, polydipsia and dehydration, and 42 are associated with renal damage [32]. Upon absorption, OTAs enter the circulatory system, bind to 43 serum proteins and accumulate in the kidneys, where they disrupt protein synthesis and other 44 pathways in proximal tubular cells. This results in the degeneration of the proximal tubules and 45 interstitial fibroses [32]. OTA is also known to bind with DNA molecules and induce renal tumors 46 in animal models, although its carcinogenic mechanism remains controversial [8, 21]. IARC 47 classified OTA as possible human carcinogen (Group 2B) [11]. Long-term exposure to OTA in 48 humans has been implicated in balkan endemic nephropathy (BEN) and associated with urinary 49 50 tract tumors, because of rather high OTA levels detected in food samples and in blood or urine from affected patients [1, 20, 28]. Pigs are the most sensitive farm animal species to the nephrotoxicity of 51 OTA. Progressive nephropathy is seen in pigs at dietary concentrations of 1 mg/kg (equivalent to 40 52 µg/kg p.c.) [4]. Dog appears to be a species that is particularly vulnerable to this mycotoxin, which 53 54 is well known for its nephrotoxic and immunosuppressive effects [3]. For example, a daily dose of 0.2 mg OTA/kg BW for 2 weeks or a single dose of 7.8 mg OTA/kg BW showed to be fatal to 55 young beagle dogs [33, 34]. Clinical symptoms of the OTA poisoning included anorexia, weight 56

loss, vomiting, tenesmus, bloody diarrhea, increased body temperature, tonsillitis, dehydration and 57 prostration. These findings were confirmed by another study in which dogs showed similar 58 symptoms at OTA doses between 0.2 and 3.0 mg/kg BW [13-15]. It was reported that six dogs died 59 in Germany in 1987, one in Scotland in 1991 and three in Korea in 2006 as a result of renal failure 60 after consumption of feed containing OTA [9, 12, 17]. In the European Union, AFB1 is the only 61 mycotoxin for which precise maximum limits have been established for complete and 62 complementary feeding stuffs intended for animals [6]. With regard to the presence of other types 63 of mycotoxins in products intended for animal feeding, including OTA, there are simple "guidance 64 65 values" [7].

Several papers have been published concerning the occurrence of OTA in pet food. Razzazi 66 et al. [30], quantified this mycotoxin in 60% of pet food samples (a total of 10 dry and 30 wet 67 foods, respectively) purchased in the Polish and Austrian markets, with analogous percentages of 68 positivity in the two types of products (40% and 43%, respectively), albeit with different levels of 69 contamination (in the range of 0.21-13.1 µg/kg and 0.22-0.8 µg/kg, in dry and wet pet foods, 70 respectively). Other studies conducted in Europe have shown, in contrast, a more sporadic OTA 71 contamination in the pet food samples examined, for the most part in rather modest concentrations, 72 always lower than 5 µg/kg [18, 22]. In a study conducted on 40 dry and wet dog foods available in 73 the Austrian and German markets, Songsermsakul et al. [31] observed a range of OTA 74 contamination (from 7 to 40 µg/kg). More recently, Gazzotti et al. [10] quantified OTA in 81% of 75 48 italian extruded pet food samples with mean concentration of $23.8 \pm 9.9 \,\mu\text{g/kg}$ and 13.0 ± 9.7 76 µg/kg for standard and premium types, respectively. All the above results are below the guidance 77 level set by European Commission, 2006. 78

The aim of the present study was to retrospectively assess the OTA plasmatic levels inhealthy and CKD dogs.

81 MATERIALS AND METHODS

Case selection review: records of client-owned dogs of different breeds, sex, age and weight 82 referred to the Mario Modenato Veterinary Teaching Hospital for nephrological consultation 83 between December 2011 and December 2013 were reviewed. Apparently healthy dogs had been 84 referred to the nephrology service, because of previous episodes of polyuria and polydipsia or 85 evaluation of overall renal function before minor surgery. For each dog, data regarding history, 86 results of biochemical analyses and urinalysis, and ultrasonographic findings were collected from 87 the medical record to confirm the diagnosis of chronic kidney disease or to include as healthy dog. 88 At the time of the initial examination, the dog's history was recorded and a complete clinical 89 90 evaluation was performed; findings of that evaluation were included in the medical record. All dog owners were asked for informed consent so that serum and plasma samples could be stored for 91 research purposes. 92

93 Renal panel with complete blood count (CBC) (5ml of blood used) and complete urinalysis 94 performed at the time of the initial examination were obtained from the medical record of each dog; 95 variables of interest included plasma concentrations of creatinine and urea and serum 96 concentrations of albumin and total protein. Inclusion criteria for dogs with CKD included 97 documented history of chronic renal disease, ultrasonographic findings and laboratory test results, 98 indicating stable CKD for at least 3 months.

Exclusion criteria for dogs were considered a documented history of acute kidney injury 99 (AKI), ultrasonographic findings or laboratory signs of AKI, and serum azotemia secondary to 100 101 urinary obstruction or volume-responsive acute kidney injury. For dogs with CKD, the stage of disease was classified according to the 2011 IRIS guidelines on the basis of plasma creatinine 102 concentration as follows: stage 1, < 1.4 mg/dl ($< 123.7 \mu \text{mol/l}$); stage 2, 1.4 to 2.0 mg/dl (123.7 to 103 176.8 μ mol/*l*); stage 3, 2.1 to 5.0 mg/d*l* (185.6 to 442 μ mol/*l*); and stage 4, > 5.0 mg/d*l* (> 442 104 µmol/l). Glomerular filtration rate was tested in each dog by means of an iohexol plasma clearance 105 assay, and results were obtained from the medical record. In the present study, plasma iohexol 106 clearance < 60 ml/min/m2 was considered to represent a decreased GFR [16, 25]. 107

OTA (from Aspergillus ochraceus) (M 403.8) reference standard was purchased from Sigma 109 (Milan, Italy). The OTA standard was dissolved in a toluene-acetic acid mixture (99:1 %, v/v) to 110 give a stock solution of 200 µg/ml which was stored at -20°C until use. Working solutions were 111 prepared by diluting daily the stock solution with the mobile phase consisting of methanol-sodium 112 phosphate buffer (pH 7.5) 50:50 % v/v. HPLC-grade water, methanol and acetonitrile were 113 purchased from VWR (Milan, Italy). The chromatographic system consisted of Jasco 880 pump and 114 Jasco 821 fluorescence detector (Jasco, Tokyo, Japan). JascoBorwin software was used for data 115 processing. The excitation wavelength (λ ex) and emission wavelength (λ em) were set at 380 and 116 420 nm. The reversed-phase column was a Luna C18 ODS2, 3 µm, (4.6 x 150mm) (Phenomenex® 117 Torrance, CA, USA). The column was kept at room temperature. The HPLC was operated with 118 mobile phase system consisting of methanol-phosphate buffer solution pH 7.5 (0.03 M Na2HPO4, 119 0.007M NaH2PO4) 50/50 % v/v at flow rate of 1 ml/min. The HPLC method was validated 120 according to [2]: selectivity, linearity, limits of determination (LOD) and quantification (LOQ), 121 repeatability and reproducibility were determined. Calibration curves were based on the analysis of 122 triplicate standards solution at 7 concentration levels in matrix. Plasma samples spiked with OTA at 123 0.025, 0.05, 0.1, 0.25, 0.5, 1 and 2 ng/ml were analyzed using extraction and HPLC method. The 124 125 experiment was repeated 5 times. Taking into account concentration step, plasma spiked samples corresponded to OTA standard concentrations of 0.1, 0.2, 0.4, 1, 2, 4 and 8 ng/ml. The repeatability 126 was tested by analyzing samples of plasma spiked with OTA at the levels of 0.05 ng/ml 127 (corresponding to 0.2 ng/ml), 0.25 ng/ml (corresponding to 1 ng/ml) and 2 ng/ml (corresponding to 128 8 ng/ml). All samples were measured in triplicates on the same day. For the within-laboratory 129 reproducibility test, each of the contamination level was tested in triplicates in seven days. The 130 results of these experiments were used also for the determination of the recovery. Selectivity studies 131 have been expressed as the ability to assess unequivocally OTA in the presence of components 132 which may be expected to be present: it has been evaluated by the comparison of free-OTA vs 133

spiked samples.

135 Samples preparation

OTA was extracted according to [24]. One ml of plasma was mixed with 5 ml of MgCl2 (0.1 M)-HCl (0.05 M) pH 1.5 solution and 5 ml of ethylacetate, vortexed for 1 min, shaked for 10 min on horizontal shaker, and then centrifuged for 10 min at 3,000 rpm. The organic phase was removed, the residue was re-extracted, with 5 ml of ethylacetate, and the organic phases were combined. Ethylacetate was evaporated to dryness under nitrogen stream and reconstituted in 250 μl of mobile phase and a 100 μl aliquote was injected into HPLC system.

142 *OTA confirmation*

For OTA positive samples, confirmation was done by OTA methyl ester formation. One hundred μl of mobile phase reconstituted sample were mixed with 300 μl of BF3 solution and the mixture was heated at 70 °C for 20 min; 50 μl of the mixture was then assayed for OTA-Me. Confirmation was based on the disappearance of the OTA peak, and the appearance of a peak corresponding to the OTA-Me.

148 *Statistical analysis*

Statistical analysis was performed with a standard software program. All data were tested for normality by means of the Kolmogorov- Smirnov test. The data are reported as mean and standard deviation. A value of p < 0.05 was considered significant. Variance analysis among mean values of OTA in healthy dogs and in dogs with IRIS stage 1, 2, 3 or 4 disease was performed by means of a ANOVA test followed by a Dunn multiple comparison test. Linear regression analysis and Spearman correlation coefficient analysis were used to assess the correlation of plasma creatinine and urea concentration and OTA levels for dogs at each stage of the IRIS classification.

158 **RESULTS**

159 *High-performance liquid chromatography method*

The calibration curve was established in the range of 0.025 to 2 ng/ml (r = 0.995). Limit of detection was equivalent to 0.0125 ng/ml. Average recovery was $81.9 \pm 3.2\%$, $89.7 \pm 0.8\%$ and $82.3 \pm 1.5\%$ respectively, in plasma samples enriched with OTA at the levels of 0.05, 0.25 and 2 ng/ml (Table 1). All results were corrected for recovery. Each positive sample was confirmed by the OTA methyl ester formation, that showed disappearance of the OTA peak (retention time: 8.5 min) (Fig. 2) and appearance of the OA methyl ester peak (retention time: 14 min).

166 *Case classification*

167 Of 102 dogs referred for nephrological consultation between December 2010 and December 168 2013, 46 were included in the study. 18 dogs of these had definitive diagnosis of CKD on the basis 169 of azotemia, low urine specific gravity, renal proteinuria (urinary protein-creatinine concentration 170 ratio, > 0.5) and abnormal renal morphology at ultrasonographic examination.

All 18 dogs were classificated and divided in different stages of kidney disease (according to
IRIS guidelines) as follows: stage 2, 5 dogs; stage 3, 6 dogs; and stage 4, 7 dogs.

In other 28 dogs, no abnormalities were detected by CBC, biochemical analyses, urinalysis or ultrasonography, although some dogs had history of previous episodes of polyuria and polydipsia. However, for purposes of the present study, plasma iohexol clearance < 60 ml/min/m2 was GFR assessments and 5 of these 28 apparently healthy dogs were considered to have early CKD and were classified as IRIS stage 1 (plasma creatinine concentration < 1.4 mg/dl [123.7 μ mol/l]). Twenty-three dogs were considered healthy and used as controls.

All dogs with stage 2, 3 or 4 disease received specific treatment for chronic kidney disease (antacids, antiemetics, vitamin B complex and renal diet) according to the severity of clinical signs. The most common clinical signs were polyuria, polydipsia, weakness, dysorexia and vomiting. Polyuria, polydipsia and weakness were present in all dogs with stage 2 CKD and only 1 dog had 183 gastrointestinal signs.

184 *OTA concentrations*

Data regarding plasma OTA concentration were tested for normality (Kolmogorov-Smirnov test) and did not follow a Gaussian distribution. Rates of OTA-positive samples, median values and ranges of OTA plasma concentrations are given in Table 2. The CKD group exhibited both a significantly (p < 0.01) higher incidence of OTA-positivity than healthy subjects (96% vs 56%) and a significantly (p < 0.001) higher median values of plasma concentrations (0.008 ng/m*l* vs 0.144 mg/m*l*). The highest OTA plasma concentration is observed in a CKD dog (1.05 ng/m*l*, i.e. 130fold the median value in healthy group).

Rates of OTA-positive samples, median values and ranges of OTA plasma concentrations for healthy dogs and dogs with stage 1, 2, 3 and 4 are given in Table 2. The median OTA for healthy dogs and dogs with stage 1, 2, 3 and 4 disease differed significantly (Kruskal-Wallis test; p = 0.0002). Results of a Dunn post test indicated that there was a significant (p < 0.01) difference in OTA levels between healthy dogs and dogs with IRIS stage 1 disease and between healthy dogs and dogs with stage 4 disease, but not between healthy dogs and dogs with stage 2 or 3 disease dogs (p > 0.05) (Fig. 3).

199 Spearman tests revealed no significant correlation between plasma OTA and both creatinine 200 (p = 0.20) and urea (p = 0.11) plasma concentrations in healthy and CKD dogs (Fig. 4).

202 **DISCUSSION**

Mycotoxins and related pathologies have become a worldwide issue and raise serious 203 sanitary problems. Studies from several countries have attempted to investigate human exposure to 204 OTA. Two approaches were undertaken: the analysis of food and the measurement of OTA in 205 biological fluids. The later was used to evaluate association of human exposure to OTA and 206 existence of human diseases, especially nephropathy [5, 19, 26]. The significance of OTA levels in 207 human plasma as a marker of OTA intake can however be questioned. Although Szczech et al. [32, 208 33] and Jeong et al. [12] have highlighted how the OTA exposure in dogs can result in serious 209 kidney damage, to the author's knowledge, this is the first study regarding OTA determination in 210 211 plasma of dogs with different stages of CKD. In the present study, CKD patients showed both higher rates of OTA positivity and median values than the healthy population. Özçelik et al. [26] 212 analyzed human plasma samples obtained from patients with different diseases of the urinary tract 213 (CKD, bladder tumors and urinary) and from healthy controls. A statistically significant difference 214 between the values of OTA present in the healthy and the sick ones was observed, with particular 215 reference to CKD patients. The values of OTA detected in the blood of sick human patients, as well 216 as those of healthy patients, are comparable with the values that we found in our study in the 217 respective groups of dogs. The present results indicate the potentially contamination of food for 218 animals with this toxin. OTA is a contaminant found not only in vegetable foods, but also in 219 matrices of animal origin, as a result of the accumulation of these compounds in muscles, organs 220 and offal (kidneys and liver, in particular), which are often used in high quantities by the pet food 221 industry, especially for the formulation of wet products [23, 27]. The results obtained in this study 222 suggest that OTA can have a role in the onset of kidney disease in dogs and the statistically 223 significant difference between patients with CKD and healthy can be attributed to decreased 224 glomerular filtration which increases the half-life of this toxin and could exacerbates its own 225 toxicity. 226

In our study, OTA plasma concentration didn't correlate with serum creatinine and urea. Furthermore, a statistically significant difference between healthy and dogs at stage 1 and stage 4 of kidney disease was observed, while no difference was observed between healthy and dogs with stages 2 and 3. These results may be explained, because of the high variability in median OTA concentration in groups 2 and 3 and also because of the small number of patients in each group.

Biomonitoring is usually used to assess internal OTA exposure resulting from dietary intake 232 and from other sources. Mycotoxin levels in blood and/or urine provide good estimates of past and 233 recent exposure, since OTA binds to serum proteins and is also partly excreted via the kidney. But, 234 measuring OTA alone does not reflect its biotransformation. The metabolism of OTA in animals 235 and humans remains to be further investigated. Metabolism of OTA in rodents, especially in rats, 236 was extensively investigated. However, the information in other species is not enough, especially 237 for companion animals as dogs. Currently, no report on metabolism of OTA in dogs is available. 238 Further studies should be carried out to understand its metabolism in companion animals. 239

Our results show that OTA is detected in almost all plasma samples tested and suggest that 240 OTA contamination is widespread in foods consumed by these animals. For these reasons, regular 241 controls should be enforced and exposure to OTA should be kept to a minimum, avoiding the 242 consumption of heavily contaminated foods. From an epidemiological point of view, OTA plasma 243 levels are considered a short-term biomarker with a high within-subject variability; therefore, they 244 245 have limited use at the individual level. However, OTA measurements can be used to characterize populations or subgroups of subjects, particularly in prospective studies storing plasma samples 246 taken at baseline, well before possibly related outcomes occur. Additional studies of dietary 247 determinants of OTA intake in animals are needed and the correlation between OTA levels and the 248 consumption of specific food should be explored. 249

250

251 **Conflict of Interest:** The authors declare that they have no conflict of interest.

253	REFERENCES
254	1. Castegnaro, M., Canadas, D., Vrabcheva,

and Pfohl-Leszkowicz, A. 2006. Balkan endemic nephropathy: Role of ochratoxins A
through biomarkers. *Mol. Nutr. Food Res.* 50: 519-29.

T., Petkova-Bocharova, T., Chernozemsky, I.N.

- Commision Decision, 2002. 2002/657/EC implementing Council Directive 96/23/EC
 concerning the performances of analytical methods and the interpretation of results, *Off. J. Eur. Comm.*, L221.
- 3. Duarte, S.C., Lino, C.M. and Pena, A. 2010. Mycotoxin food and feed regulation and the
 specific case of ochratoxin A: a review of the worldwide status. *Food Addit. Contam.* 27:
 1440-1445.
- 4. EFSA. 2004. Opinion of the Scientific Panel on Contaminants in Food Chain on a request
 from the Commission related to ochratoxin A (OTA) as undesirable substance in animal
 feed. *EFSA J.* 101: 1-36.
- 5. Eko-Ebongue, S., Antalick, J.P., Bonini, M., Betbeder, A.M., Faugère, J.G., Maaroufi, K.,
 Bacha, H., Achour, M., Grosse, Y., Pfohl-Leszkowicz, A. and Creppy, E.E. 1994.
 Détermination des teneurs en ochratoxine A, vitamine E et vitamine A dans les sérums
 humains de France et de Tunisie : recherche d'une corrélation. *Annales des Falsifications et de l'Éxpertise Chimique et Toxicologique* 929: 213-224.
- European Commission (EC). 2002. Council Directive (EC) No 32/2002 of 7 May 2002 on
 undesirable substances in animal feed. *Off. J. Eur. Un.*,L140: 10-22.
- 273 7. European Commission (EC). 2006. Commission Recommendation (EC) No 576/2006 of 17
 274 August 2006 on the presence of deoxynivalenol, zearalenone, ochratoxin A, T-2 and HT-2
 275 and fumonisins in products intended for animal feeding. *Off. J. Eur. Un.*,L229: 7-9.

- Faucet, V., Pfohl-Leszkowicz, A., Dai, J., Castegnaro, M. and Manderville, R.A. 2004.
 Evidence for covalent DNA adduction by ochratoxin A following chronic exposure to rat
 and subacute exposure to pig. *Chem. Res. Toxicol.* 17: 1289-1296.
- 9. Gareis, M., Reubel, G., Kröning, T. and Porzig, R. 1987. Ein Fall von infektiösem
 Welpensterben bei Afaghanen in Verbindüng mit der Verfutterung von Ochratoxin A –
 haltigem Milchpulver. *Tieraerztliche Umschau* 42: 77-80.
- 282 10. Gazzotti, T., Biagi, G., Pagliuca, G., Pinna, C., Scardilli, M., Grandi and M., Zaghini, G.
 283 2015. Occurrence of mycotoxins in extruded commercial dog food. *Anim. Feed Sci.*284 *Technol.* 202: 81-89.
- International Agency for Research on Cancer (IARC). Ochratoxin A. In Some Naturally
 Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and
 Mycotoxins; World Health Organization: Geneva, Switzerland, 1993.
- 12. Jeong, W.I., Do, S.H., Jeong, D.H., Chung, J.Y., Yang, H.J., Yuan, D.W., Hong, I.H., Park,
 J.K., Goo, M.J. and Jeong, K.S. 2006. Canine renal failure syndrome in three dogs. Journal
 of Veterinary Science 7, 299-301.
- 13. Kitchen, B.N., Carlton, W.W. and Hinsman, E.J. 1977c. Ochratoxin A and citrinin induced
 nephrosis in beagle dogs. III. Terminal renal ultrastructural alterations. *Vet. Pathol.* 14: 392 406.
- 14. Kitchen, B.N., Carlton, W.W. and Tuite, J. 1977a. Ochratoxin A and citrinin induced
 nephrosis in beagle dogs. I. Clinical and clinicopathological features. *Vet. Pathol.* 14: 154172.
- 15. Kitchen, B.N., Carlton, W.W. and Tuite, J. 1977b. Ochratoxin A and citrinin induced
 nephrosis in beagle dogs. II. Pathology. *Vet. Pathol.* 14: 261-272.
- 16. Lippi, I., Meucci, V., Guidi, G. and Soldani, G. 2008. Valutazione della velocità di
 filtrazione glomerulare mediante clearance plasmatica dello ioexolo nel cane: confronto tra
 metodi semplificati. Veterinaria 1: 1-8.

302	17. Little, C.J.L., McNeil, P.E. and Robb, J. 1991. Hepatopathy and dermatitis in a dog
303	associated with the ingestion of mycotoxins. J. Small Anim. Pract. 32: 23-26.
304	18. López Grío, S.J., Garrido Frenich, A., Martínez Vidal, J.L. and Romero-González R. 2010.
305	Determination of aflatoxins B1, B2, G1 G2 and ochratoxin A in animal feed by ultra-high-
306	performance liquid chromatography-tandem mass spectrometry. Journal of Separation
307	Science 33: 502-508.
308	19. Maaroufi, K., Achour, A., Betbeder, A.M., Hammami, M., Ellouz, F., Creppy, E.E. and
309	Bacha, H. 1995. Foodstuffs and human blood contamination by the mycotoxin ochratoxin
310	A: correlation with chronic interstitial nephropathy in Tunisia. Arch. Toxicol. 69: 552-558.
311	20. Mally, A., Hard, G.C. and Dekant, W. 2007. Ochratoxin A as a potential etiologic factor in
312	endemic nephropathy: Lessons from toxicity studies in rats. Food Chem. Toxicol. 45: 2254-
313	2260.
314	21. Mally, A., Zepnik, H., Wanek, P., Eder, E., Dingley, K., Ihmels, H., Volkel, W. and Dekant,
315	W. 2004. Ochratoxin A: Lack of formation of covalent DNA adducts. Chem. Res. Toxicol.
316	17: 234-242.
317	22. Martins, M.L., Martins, H.M. and Bernardo, F., 2003. Fungal flora and mycotoxins
318	detection in commercial pet food. Revista Portuguesa de Ciencias Veterinarias 98, 179-183.
319	23. Matrella, R., Monaci, L., Milillo, M.A., Palmisano, F. and Tantillo, M.G., 2006. Ocratoxin
320	A determination in paired kidneys and muscle samples from swine slaughtered in southern
321	Italy. Food Control 17: 114-117.
322	24. Meucci, V., Costa, E., Razzuoli, E., Mengozzi, G., and Soldani, G. 2005. Occurence of
323	ochratoxin a in blood of italian slaughtered pigs. Toxicol. Lett. 158: S116.
324	25. Meucci, V., Gasperini, A., Soldani, G., Guidi, G. and Giorgi, M. 2004. A new HPLC
325	method to determine glomerular filtration rate and effective renal plasma flow in conscious
326	dogs by single intravenous administration of iohexol and p-aminohippuric acid. J .
327	Chromatogr. Sci. 42: 107-111.

328	26. Ozcelik, N., Kosar, A. and Soysal, D. 2001. Ochratoxin A in human serum samples
329	collected in Isparta-Turkey from healthy individuals and individuals suffering from different
330	urinary disorders. Toxicol. Lett. 121: 9-13.

- 27. Pfohl-Leszkowicz, A. and Manderville, R.A., 2007. Ochratoxin A: an overview on toxicity
 and carcinogenicity in animals and humans. *Mol. Nutr. Food Res.* 51: 61-99.
- 28. Pfohl-Leszkowicz, A., Tozlovanu, M., Manderville, R., Peraica, M., Castegnaro, M. and
 Stefanovic, V. 2007. New molecular and field evidences for the implication of mycotoxins
 but not aristolochic acid in human nephropathy and urinary tract tumor. *Mol. Nutr. Food Res.* 51: 1131-1146.
- 29. Polzin, D.J. 2011. Chronic Kidney Disease. In: Bargtes, J., Polzin, D.J. (Eds.), Nephrology
 and Urology of Small Animals. Wiley-Blackwell, Ames, pp. 433-471.
- 339 30. Razzazi, E., Böhm, J., Grajewski, J., Szczepaniak, K., Kübber-Heiss, A.J. and Iben, C.H.,
 2001. Residues of ochratoxin A in pet foods, canine and feline kidneys. *J. Anim. Physiol.*341 *Anim. Nutr.* 85: 212-216.
- 342 31. Richard, J.L. 2007. Some major mycotoxins and their mycotoxicoses- An overview. *Int. J.* 343 *Food Microbiol.* 119: 3-10.
- 344 32. Songsermsakul, P., Razzazi-Fazeli, E., Böhm, J., Zentek, J., 2007. Occurrence of 345 deoxynivalenol (DON) and ochratoxin A (OTA) in dog foods. *Mycotoxin Res.* 23: 65-67.
- 33. Szczech, G.M., Carlton, W.W. and Tuite, J. 1973a. Ochratoxicosis in beagle dogs I. Clinical
 and clinicopathological features. *Vet. Pathol.* 10: 135-154.
- 34. Szczech, G.M., Carlton, W.W. and Tuite, J. 1973b. Ochratoxicosis in beagle dogs II
 Pathology. *Vet. Pathol.* 10: 219-231.

- 353 Figure legend:
- Fig. 1. Chemical structure of OTA.
- Fig. 2. Chromatogram of a OTA naturally-contaminated serum sample of a CKD dog (line A) and
- 356 OTA standard dilution (10 ng/ml in HPLC mobile phase) (line B).
- Fig. 3. Concentrations of OTA in canine plasma of healthy dogs and IRIS stages 1, 2, 3 and 4 CKD
- dogs; Different letters (a, b) are used to report statistically significant differences (p < 0.05).
- Fig. 4. Spearman correlation analysis between plasma creatinine (mg/dl) and urea (mg/dl) and serum OTA levels (ng/ml) in healthy and CKD dogs.


Parameters				
LOD	0.0125 ng/m <i>l</i>			
LOQ	0.0250 ng/ml			
\mathbf{r}^2	0.995 (n = 5 replicates)			
CV % (intra-day)	· · · · ·			
0.05	5.8 (n = 3 replicates)			
0.25	8.9 (n = 3 replicates)			
2.00	4.3 (n = 3 replicates)			
CV % (inter-day)				
0.05	9.7 (n = 21 replicates)			
0.25	8.3 (n = 21 replicates)			
2.00	7.0 (n = 21 replicates)			
Recovery %				
0.05	81.9 ± 3.2 (n = 21 replicates)			
0.25	89.7 ± 0.8 (n = 21 replicates)			
2.00	82.3 ± 1.5 (n = 21 replicates)			

LOD: limit of detection; LOQ: limit of quantification; CV: coefficient of variation.


Table 2. Concentrations of OTA in plasma of healthy, CKD and IRIS stages 1, 2, 3 and 4


dogs.

Group	N.	Median (range) ng/m <i>l</i>	% of positives
Healthy	23	0.008 (<lod-0.27)< td=""><td>56% (13 of 23)</td></lod-0.27)<>	56% (13 of 23)
CKD	23	0.144 (<lod-1.05)< td=""><td>96% (22 of 23)</td></lod-1.05)<>	96% (22 of 23)
IRIS stage 1	5	0.580 (0.007-1.050)	100% (5 of 5)
IRIS stage 2	5	0.050 (<lod-0.686)< td=""><td>80% (4 of 5)</td></lod-0.686)<>	80% (4 of 5)
IRIS stage 3	6	0.101 (0.031-0.683)	100% (6 of 6)
IRIS stage 4	7	0.221 (0.061-0.725)	100% (7 of 7)














Fig. 4